The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model

David FC Gibson; Delinda A. Johnson; Susan M. Langan-Fahey; Mary K. Lababidi; William H. Wolberg; V. Craig Jordan

doi:10.1007/BF00665699

The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model

David FC Gibson, Delinda A. Johnson, Susan M. Langan-Fahey, Mary K. Lababidi, William H. Wolberg, V. Craig Jordan

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The development of endometrial cancer is a potential risk during long-term tamoxifen therapy for breast cancer. In order to protect the uterus, progestin treatment has been proposed for these patients. However, within the 7,12-dimethylbenzanthracene-induced rat mammary model, progesterone is known to reverse the antitumor effects of tamoxifen. This study shows that progesterone administered intermittently still reverses the antitumor effects of tamoxifen in this model. This effect of progesterone is not due to a decrease in the tissue levels of tamoxifen, and may be direct, via the progesterone receptor.

Original language	English (US)
Pages (from-to)	283-287
Number of pages	5
Journal	Breast Cancer Research and Treatment
Volume	27
Issue number	3
DOIs	https://doi.org/10.1007/BF00665699
State	Published - Jan 1993
Externally published	Yes

Keywords

7,12-dimethylbenzanthracene
progesterone
rat mammary tumor
tamoxifen

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/BF00665699

Cite this

@article{b7b200aa18d14c07909a1e531203ef7d,

title = "The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model",

abstract = "The development of endometrial cancer is a potential risk during long-term tamoxifen therapy for breast cancer. In order to protect the uterus, progestin treatment has been proposed for these patients. However, within the 7,12-dimethylbenzanthracene-induced rat mammary model, progesterone is known to reverse the antitumor effects of tamoxifen. This study shows that progesterone administered intermittently still reverses the antitumor effects of tamoxifen in this model. This effect of progesterone is not due to a decrease in the tissue levels of tamoxifen, and may be direct, via the progesterone receptor.",

keywords = "7,12-dimethylbenzanthracene, progesterone, rat mammary tumor, tamoxifen",

author = "Gibson, {David FC} and Johnson, {Delinda A.} and Langan-Fahey, {Susan M.} and Lababidi, {Mary K.} and Wolberg, {William H.} and Jordan, {V. Craig}",

year = "1993",

month = jan,

doi = "10.1007/BF00665699",

language = "English (US)",

volume = "27",

pages = "283--287",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model

AU - Gibson, David FC

AU - Johnson, Delinda A.

AU - Langan-Fahey, Susan M.

AU - Lababidi, Mary K.

AU - Wolberg, William H.

AU - Jordan, V. Craig

PY - 1993/1

Y1 - 1993/1

N2 - The development of endometrial cancer is a potential risk during long-term tamoxifen therapy for breast cancer. In order to protect the uterus, progestin treatment has been proposed for these patients. However, within the 7,12-dimethylbenzanthracene-induced rat mammary model, progesterone is known to reverse the antitumor effects of tamoxifen. This study shows that progesterone administered intermittently still reverses the antitumor effects of tamoxifen in this model. This effect of progesterone is not due to a decrease in the tissue levels of tamoxifen, and may be direct, via the progesterone receptor.

AB - The development of endometrial cancer is a potential risk during long-term tamoxifen therapy for breast cancer. In order to protect the uterus, progestin treatment has been proposed for these patients. However, within the 7,12-dimethylbenzanthracene-induced rat mammary model, progesterone is known to reverse the antitumor effects of tamoxifen. This study shows that progesterone administered intermittently still reverses the antitumor effects of tamoxifen in this model. This effect of progesterone is not due to a decrease in the tissue levels of tamoxifen, and may be direct, via the progesterone receptor.

KW - 7,12-dimethylbenzanthracene

KW - progesterone

KW - rat mammary tumor

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0027524843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027524843&partnerID=8YFLogxK

U2 - 10.1007/BF00665699

DO - 10.1007/BF00665699

M3 - Article

C2 - 8312587

AN - SCOPUS:0027524843

SN - 0167-6806

VL - 27

SP - 283

EP - 287

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -

The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this